noiiglutide (SHR20004) / Jiangsu Hengrui Pharma - LARVOL DELTA

Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus. (PubMed, Diabetes Obes Metab) - "Daily administration of noiiglutide using a titration method was well tolerated by Chinese obese participants without DM and showed potential therapeutic effect for weight loss."

Journal • PK/PD data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Benefits of HR17031, a Fixed-Ratio Combination of INS068 and SHR20004, vs. Its Components Alone in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Oral Antidiabetic Drug(s) (OADs) (ADA 2024) - "This trial assessed efficacy and safety of HR17031 vs INS068 and SHR20004 in pts with T2D. In this randomized phase 2 trial, 455 Chinese adults with T2D (HbA1c 7.5%-11.0%; previous metformin±another OAD) were randomized (2:2:1) to daily injections of HR17031 (n = 183), INS068 (n = 182) or SHR20004 (0.12 mg/d; n = 90). HR17031 is effective and well-tolerated in pts with T2D uncontrolled on OAD(s)."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial. (PubMed, Diabetes Obes Metab) - "In obese Chinese adults without diabetes, once-daily subcutaneous noiiglutide significantly reduced body week at week 24 compared with placebo, and had a manageable safety profile, primarily involving gastrointestinal disorders."

Clinical • Journal • P2 data • Diabetes • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Obesity

Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=455 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects. (clinicaltrials.gov) - P2 | N=128 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Unknown status ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics of HR17031 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=450 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - P2 | N=254 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - P2; N=252; Enrolling by invitation; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Recruiting ➔ Enrolling by invitation

Clinical • Enrollment status • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Pharmacokinetics of HR17031 Injection in Healthy Subjects (clinicaltrials.gov) - P1; N=24; Active, not recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics of HR17031 Injection in Healthy Subjects (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - P2; N=252; Recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - P2; N=252; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Clinical • New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity